{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-000678","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.523055+00:00","generated_at":"2026-06-15T00:48:43.394092+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lipella Pharma Q1 net loss $1.1M; cash $4.0M; Phase 2a LP-10 positive","bullets":["Net loss of ~$1.1M for Q1 2023; cash, equivalents, and marketable securities ~$4.0M as of March 31, 2023.","Phase 2a trial for LP-10 (hemorrhagic cystitis) showed positive safety and efficacy top line results; Type B FDA meeting planned in coming months.","Established Scientific Advisory Board for LP-310 (oral lichen planus) with five experts in oral medicine.","Entered manufacturing collaboration with Cook MyoSite to support LP-10 IND application."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-000678","json":"https://secwatch.observer/filing/0001753926-23-000678.json","markdown":"https://secwatch.observer/filing/0001753926-23-000678.md","text":"https://secwatch.observer/filing/0001753926-23-000678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000678/0001753926-23-000678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000678/g083547_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:48:43.394092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36540e30ae928ee295e543677f27ce55478c4633","claim":"LIPELLA PHARMACEUTICALS INC. reported quarter ended March 31, 2023 results: net income approximately $1.1 million.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023 was approximately $1.1 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000678/0001753926-23-000678-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"approximately $1.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}